Kornimate/medical-research-clean huggingface dataset:
trial of computerized sbi to reduce teen alcohol use

Conditions: Alcohol Abuse; Cannabis Abuse; Nicotine Dependence

Summary: the goal of this project is to test the effectiveness of a computer-facilitated alcohol screening and brief intervention (c-asbi) system for 12- to 18-year-old primary care patients in a multi-site, randomized comparative effectiveness trial. the investigators hypothesize that, among 12- to 18-year olds patients coming for annual well-care, those receiving c-asbi will have lower rates of any alcohol use at 3-, 6-, and 12-month follow-ups compared to treatment as usual (tau).

the specific aims are to 1) test the effects of c-asbi on any alcohol use; 2) test the effects of c-asbi separately as a prevention, therapeutic, and risk-reduction intervention; 3) test the effects of c-asbi separately on cannabis and tobacco use; explore its effects on other drug use; and 4) assess potential moderators (e.g., age, gender, race/ethnicity, substance use history +/-, parent/sibling/peer substance use), mediators (e.g., youth to provider connectedness,20 perceived harmfulness of alcohol and drug use), and explore c-asbi's mechanism of action.

Eligibility criteria:
inclusion criteria: * arriving for well or non-emergent care at one of participating study sites * have an email address * have internet address exclusion criteria: * unable to read or understand english * living away at college at the time of the recruitment visit * not available for computer/telephone follow-ups * judged by the provider to be medically or emotionally unstable at time of visit

Keywords: substance use alcohol abuse cannabis abuse nicotine dependence adolescents
using decision analysis to enhance decision-making regarding prostate cancer screening

Conditions: Prostate Cancer

Summary: the purpose of this study is to evaluate a new counseling tool for patients deciding whether or not to undergo prostate cancer screening. this screening decision aid is a computer program that provides individual patients estimates of their risks of prostate cancer diagnosis, prostate cancer related death, or death from any cause. the researchers are evaluating whether or not patients find this screening decision aid helpful. as part of this study, participants will be asked for their response on questionnaires. if patients find the screening decision aid helpful, the researchers will make it available at other clinic locations.

to conduct a feasibility study on implementing the computer-based screening decision aid for prostate cancer screening in a primary care setting during a 60-minute interview. to aid in informed decision making, the screening decision aid will include a graphical representation of predicted probabilities of prostate cancer diagnosis, prostate cancer-specific mortality, death from competing causes based on a man's unique demographic information. the study team will provide standardized counseling followed by individualized counseling with the screening decision aid. it will assess the quality of the decision making process (patient feels knowledgeable, informed of the risks/benefits, feels clear about their values, is involved in the decision), and quality of the decision.

Eligibility criteria:
inclusion criteria: * life expectancy \> 10 years * ability to read english exclusion criteria: * personal history of prostate cancer * personal history of prostate biopsy or prostate surgery * prior prostate specific antigen screening in the past year leading up to their scheduled clinic visit * cognitive impairment

Keywords: decision aid
a study of tas0728 in patients with solid tumors with her2 or her3 abnormalities

Conditions: Advanced Solid Tumors With HER2 Abnormalities; Advanced Solid Tumors With HER3 Abnormalities

Summary: this is a first-in-human (fih), 2-part, phase 1/2, open-label, multicenter study design to evaluate the safety, tolerability, pk, pharmacodynamics, pgx, and efficacy of tas0728. this study consists of phase 1 and phase 2 components in subjects with advanced solid tumors with her2 or her3 overexpression, amplification, or mutation who have progressed despite standard therapy or for which no standard therapy exists, particularly urothelial cancer, biliary tract cancer, metastatic breast cancer, non-small cell lung cancer and colorectal cancer.


Eligibility criteria:
inclusion criteria: 1. male or females with an age ≥ 18 years. 2. subjects with histological- or cytological-confirmed, advanced cancer, who have progressed on (or not been able to tolerate) standard therapy or for whom no standard anticancer therapy exists 1. for phase 1, only subjects her2 or her3 molecular/genetic alterations will be enrolled. 2. for phase 2a, subjects with one of the following tumor types will be enrolled: i. urothelial cancer with her2 or her3 mutation ii. biliary tract cancer with her2 or her3 mutation iii. breast cancer with her2 or her3 mutation iv. breast cancer with her2 amplification or overexpression v. nsclc with her2 or her3 mutation vi. crc with her2 mutation or amplification vii. other tumors with her2 mutation/amplification/overexpression or her3 mutation (gastric/gej, endometrial). 3. at least 1 measurable lesion for solid tumor 4. is able to take medications orally (e.g., no feeding tube). 5. able to agree to and sign informed consent and to comply with the protocol 6. has adequate organ function exclusion criteria: 1. has a serious illness or medical condition(s) 2. has received treatment with any proscribed treatments within specified time frames prior to study drug administration 3. impaired cardiac function or clinically significant cardiac disease

Keywords: phase i solid tumors pharmacokinetics pharmacodynamics mtd tas0728 her2 her3 mutation amplification or overexpression urothelial cancer with her2 or her3 mutation biliary tract cancer with her2 or her3 mutation mbc with her2 amplification or overexpression or her3 mutation nsclc with her2 or her3 mutation crc with her2 or her3 mutation amplification
factors influencing patient satisfaction in a glaucoma population

Conditions: Glaucoma

Summary: 1. to administer a questionnaire to patients seen by wills eye glaucoma department physicians at wills eye hospital assessing satisfaction with their office visit, vision related quality of life, and related issues. 2. to collect and de-identify information from each participant's medical chart related to their care including information pertaining to demographics, disease severity, and prior and current treatment 3. to assess the correlations between demographic factors, vision related quality of life, eye disease, and treatments with patient satisfaction survey responses.

this prospective study aims to recruit up to 250 patients being seen by glaucoma specialists at wills eye hospital. informed consent will be obtained prior to the office visit. patients will complete a satisfaction survey with a few additional questions about themselves and their vision. electronic health records (ehr) will be used to collect race, gender, age, glaucoma diagnosis, current and prior treatments, timing of appointment and care, visual acuity and field data, and distance to patient's home. additional information captured will include weather, time of day, day of week. in addition to completing the questionnaire subjects will be asked to provide their name and date of birth. trained research staff members will use this information to find patients on the ehr system. a research assistant will later abstract information from the patient's ehr. this information will be tagged to the survey by a unique identifier, but all patient identity related information will be removed, including name and date of birth. patients will be made aware that research staff will be retrieving their protected health information (phi) for the purpose of this study through the consent form.

Eligibility criteria:
inclusion criteria: age \> 18 years; patients who have a scheduled appointment at with a glaucoma specialist at wills eye hospital; diagnosis of glaucoma or glaucoma suspect exclusion criteria: children under the age of 18; inability to give informed consent; patients who are physically and/or mentally incapable of filling out a paper survey; patients who are not literate in english.

Keywords: glaucoma care quality of life patient satisfaction
study of safety, tolerability and effects of pf-05175157 in adults with moderate to severe acne vulgaris

Conditions: Acne Vulgaris

Summary: this is a 6 week study to characterize the safety, tolerability and effects of pf-05175157 administered for 6 weeks in subjects with moderate to severe acne vulgaris.


Eligibility criteria:
inclusion criteria: * males 18 years or older diagnosed with moderate to severe acne vulgaris who are otherwise healthy. * normal spirometry at screening (fev1 and fvc (forced vital capacity)at least 80% predicted). * minimum of 20 inflammatory lesions on the face. * willing to discontinue other acne treatments prior to and during the study period through follow-up. exclusion criteria: * subjects with active nodulocystic acne. * subjects unwilling to comply with lifestyle guidelines, commit to study visits, and perform study procedures. * history of dry eye or other known disease that affects the sclera or cornea. * history of pulmonary disease or inability to adequately perform testing.

Keywords: safety tolerability pharmacokinetics oral dosing moderate to severe acne vulgaris
a trial of project impact in early intervention

Conditions: Autism Spectrum Disorder

Summary: our pilot study will address a number of pressing questions, including: can community clinicians successfully coach parents of children with asd in evidence-based practice to achieve positive outcomes for their children and themselves? what dose is necessary to achieve change? and what is the cost effectiveness of implementing evidence-based interventions at different doses?

the investigators will partner with 6 of philadelphias 13 agencies serving young children with asd. the investigators will enroll 3 clinicians per agency (18 total) and 3 families per clinician (54 total). agencies will be randomized to the 3 arms. the investigators will measure clinician fidelity and parent fidelity through direct observation and selfreport. the investigators will measure child and parent outcomes at baseline and 6 months using measures common to similar trials. resource use for the economic evaluation will occur quarterly and will take a societal approach. the investigators will partner with a community advisory board to apply the findings from this pilot trial to the development of a larger, system-wide subsequent trial that is feasible and ecologically valid for philadelphias ei system. the results will provide rigorous information about whether evidence-based autism interventions for young children can be implemented successfully with the resources available in cities like philadelphia, the role of hours of treatment in improving child outcomes, and the cost-benefit implications for families and community agencies. this project has the potential to dramatically improve the services families of young children with asd in philadelphia receive, and significantly improve their long-term outcomes. this preliminary trial would provide the ei system with the information needed to bring this type of intervention to scale across the entire system. it also would serve as the foundation for an application for federal funds to conduct a system-wide study of project impact as implemented in all philadelphia agencies serving children with asd.

Eligibility criteria:
inclusion criteria: 1. child is \<30 months of age (to receive 6 months of intervention) 2. a classification of autism or high autism risk as determined by the ei system; 3. receive early intervention services through the infant and toddler program; and 4. parent is willing to complete the parent measures that are part of this study. exclusion criteria: 1) be over 30 months of age
the analysis of factors causing indwelling urinary catheter-related infections in icu patients and their nursing strategies

Conditions: Catheter-associated Urinary Tract Infection

Summary: to explore the analysis of factors causing indwelling urinary catheter-related infections in icu patients and their nursing strategies, and to provide reference for clinical nursing work. 291 patients with indwelling urinary catheters in the second area of icu of our hospital from january 1, 2023 to september 30, 2023 were selected as research subjects. they were divided into infection group and non-infection group according to the presence or absence of urinary tract infection. non-infection group the first group consisted of patients without urinary tract infection (278 cases), and the infection group consisted of patients with urinary tract infection (13 cases). a retrospective analysis method was used to analyze the causes of catheter-related urinary tract infection and the infecting bacteria of the two groups of patients. a single factor analysis was performed on various factors and other related factors, and corresponding nursing strategies were summarized and proposed.


Eligibility criteria:
inclusion criteria: * age \> 14 years * patients with indwelling urinary tube during hospitalization * length of stay in icu \> 48h * complete hospitalization data exclusion criteria: * had urinary tract infection before hospitalization * indwelling catheter \< 72h * severe liver and kidney failure and death within 48 hours of admission

Keywords: icu catheter-associated factors nursingcountermeasures
vitamin e on staple line and anastomoses of roux-en-y gastric bypass

Conditions: Postoperative Pain

Summary: patients will be randomized into 2 groups: * vit e group: vitamin e ointment will be applied over staple lines and anastomoses * control group: vitamin e will not be applied postoperative pain will be assessed 24 hours after surgery.

patients will be randomized into 2 groups: * vit e group: vitamin e acetate ointment will be applied over staple lines and anastomoses in roux-en-y gastric bypass. * control group: vitamin e will not be applied postoperative pain will be assessed 24 hours after surgery, by means of visuala analogic scale (ranging from 0 to 100mm).

Eligibility criteria:
inclusion criteria: * bmi \>40 kg/m2 or \>35 kg/m2 associated to obesity-related comorbidities * patients undergoing roux-en-y gastric bypass as bariatric procedure * patients accepting to participate in the study and signing and informed consent form exclusion criteria: * patients undergoing other bariatric techniques * patients undergoing roux-en-y gastric bypass as revisional procedure
swiss kidney stone cohort (sksc)

Conditions: Kidney Stone

Summary: the sksc is a continuous database with the objective of a standardized diagnosis and monitoring of patients with kidney stones as well as the establishment of a biobank.

the objective of this study is multi-site, standardized observation and characterization of kidney stone patients. furthermore, an adequate structure should be established for the execution of studies with kidney stone patients, in order to then, if necessary, develop recommendations for useful monitoring or prophylactic measures, as well as new treatment options for kidney stone patients. a control group of 250 stone-free volunteers matching patients cohort participants for sex and age started recruitment in october 2017 and will serve the purpose of comparison in future studies.

Eligibility criteria:
for sksc patients group: inclusion criteria: only patients that meet all of the following inclusion criteria can be included in this study: * signed declaration of informed consent * male or female * recurrent kidney stone episodes (more than 1) or an individual kidney stone episode with one or several of the following risk factors: * the first manifestation at the a minimum age of 25 * positive family history * non-calcium oxalate stones * gastrointestinal disorders (e.g. gastric bypass surgery, inflammatory bowel disease, malabsorption etc.) * osteoporosis * nephrocalcinosis * single kidneyness * currently pregnant * gout * metabolic syndrome ( diabetes mellitus type i and ii ) * residual calculi (at least 3 months after the therapy) * bilateral or multiple stones * chronic urinary tract infection * chronic renal failure (egfr lower than 60 ml/min.) * kidney transplant exclusion criteria: patients with at least one of the following exclusion criteria may not take part in this study. * not signed informed consent form * age below 18 years old for sksc control group inclusion criteria: * signed declaration of informed consent * male or female * kidney-stone free (screening verification by low-dose ct-scan) exclusion criteria: * not signed informed consent form * age below 18 years old * pregnancy * history of kidney stones * low-dose ct-scan positive for kidney stones during screening phase

Keywords: kidney stone
omega-3 fatty acids in tourette's disorder

Conditions: Tourette's Disorder

Summary: this study examines the safety and efficacy of omega-3 fatty acids (fish oil) for the treatment of tourette's disorder.

this is a 20-week, double-blind, placebo (olive oil) controlled study examining supplemental fish oil in the treatment of tic and ocd symptoms.

Eligibility criteria:
inclusion criteria: * ages 6 through 18 inclusive * meet full dsm-iv diagnostic criteria for td or chronic motor tic disorder * normal laboratory results, including serum chemistries, hematology, and urinalysis * must be able to swallow capsules. * must be of normal intelligence in the judgment of the investigator. * subjects and parents must possess an educational level, degree of understanding and command of the english language to enable them to communicate suitably with the investigator and study coordinator and to understand the nature of the study. * subjects and their legal representatives must be considered reliable. exclusion criteria: * organic brain disease, for example, traumatic brain injury residua * meeting criteria for mental retardation as defined by the dsm-iv. * a history of seizure disorder (other than febrile seizure). * a subjects with history of sydenham's chorea. * autism, schizophrenia or other psychotic disorders. * a primary diagnosis of a major mood disorder that requires ongoing psychiatric treatment. * a neurological disorder other than a tic disorder. * a documented auto-immune disorder. * a major medical illness. * a history of ongoing or previously undisclosed child abuse (risk of removal from home would not allow for consistent caretaker ratings). * subjects who, in the opinion of the investigator, are unsuitable in any other way to participate in this study.

Keywords: tourette's disorder, obsessive-compulsive disorder, tics
easi access ii --- follow-up study to the easi access trial

Conditions: Disaster Medicine; Difficult Intravenous Access; Dehydration

Summary: test whether basic life support (bls) providers can successfully place enzymatically augmented subcutaneous infusion (easi) access lines for subcutaneous infusion, and characterize intravascular absorption of easi-administered (tracer-labelled) glucose (d5w).


Eligibility criteria:
inclusion criteria: * subjects will be at least 18 years of age and have none of the following conditions: * pregnancy (negative urine pregnancy test to be performed before study participation), * diabetes, or coagulopathic (including taking any anticoagulants); * subjects cannot be taking steroids or other immunosuppressants. * because of the potential for reduced hyaluronidase effectiveness, the study excludes patients taking more than 80 mg daily aspirin, as well as any patients taking acth, antihistamines, or estrogen other than in oral contraceptive preparations. * subjects will not be required to fast before the study, but will not allowed to eat or drink during the easi infusion or the phlebotomy sampling time frame.

Keywords: disaster mass casualty incident prehospital rehydration intravascular access
diagnostic performance of on-site automatic coronary computed tomography angiography-derived fractional flow reserve

Conditions: Coronary Artery Disease

Summary: the current study evaluated the diagnostic performance for myocardial ischemia of on-site automatic ccta-derived ffr (ct-ffr) using a commercially available workstation as compared with invasive ffr as a reference. the diagnostic performance of ct-ffr was compared to that of ccta diameter stenosis.

this is a retrospective, multicenter, comparative, investigator-initiated study to evaluate the diagnostic performance of ct-ffr from routinely acquired ccta data using the software heartmedi+ 1.0 (ai medic, korea) to detect hemodynamically significant cad. patients who underwent ccta within 90 days before invasive coronary angiography and ffr measurement will be screened in each participating center. after that, invasive coronary angiography, ffr data, and ccta data will be anonymized and transferred to the independent core laboratories and analyzed in a blind fashion. the presence of ischemia was defined as ffr ≤0.80. anatomical obstructive stenosis was defined as diameter stenosis on ccta ≥50%, and the diagnostic performance of ct-ffr and ccta stenosis for ischemia was compared.

Eligibility criteria:
inclusion criteria: * adults aged 20 years or older * individuals who had undergone ≥ 64 multidetector row ccta within 90 days before invasive coronary angiography and ffr measurement * individuals who had not experienced any clinical events or significant clinical changes between the time of ccta and invasive coronary angiography exclusion criteria: * previous coronary intervention or coronary bypass surgery in the target vessel * invasive coronary angiography under unstable conditions * previous myocardial infarction at target vessel territory * congenital heart disease * moderate or severe valvular heart disease * previous valvular heart surgery * left ventricular ejection fraction ≤40% or left ventricular hypertrophy * previous cardiac device implantation * body mass index \>35 kg/m2 * poor ffr tracing quality * no information on the position of the ffr pressure wire * heart rate ≥100 beats/min during ccta * ccta calcium score ≥1000 * no nitroglycerin prior to ccta * ccta slice thickness \>1.0 mm * significant artifacts in ccta

Keywords: computed tomography-based fractional flow reserve coronary computed tomography angiography fractional flow reserve coronary artery disease